Brief: Astria Therapeutics Receives FDA Orphan Drug Designation For Navenibart (Star-0215)

Astria Therapeutics

30/09/2024 13:05

Sept 30 (Reuters) - Astria Therapeutics Inc  ATXS.O :
    * ASTRIA THERAPEUTICS RECEIVES FDA ORPHAN DRUG DESIGNATION
FOR
NAVENIBART (STAR-0215) FOR THE TREATMENT OF HEREDITARY
ANGIOEDEMA
    * ASTRIA THERAPEUTICS: TO SHARE ADDITIONAL RESULTS FROM
ALPHA-STAR
TRIAL IN Q4 & TO PROGRESS NAVENIBART INTO PHASE 3 TRIAL
INITIATING IN Q1  2025

Source text for Eikon:  urn:newsml:reuters.com:*:nBw7jKMRNa
Further company coverage:  ATXS.O 

 ((Reuters.Briefs@thomsonreuters.com;))